Fig. 2: UHRF1 restrains CD8+ T cell response through downregulate MHC-I expression.

a, b Flow cytometry analysis of tumor-infiltrating lymphocytes. shNT or shUhrf1 LLC-OVA cells were injected into female C57BL/6 mice, tumors were collected on day 17 for analysis, n = 7 (shNT), 8 (shUhrf1) (a); sgNT or sgUhrf1 LG1233 cells were injected into female C57BL/6 mice, tumors were collected on day 8 for analysis, n = 10 per group (b). c, d Tumor growth curves of tumor bearing female C57BL/6 mice treated with IgG or anti-CD8 neutralizing antibodies. n = 6 (shNT), 7 (shUhrf1 + IgG, shUhrf1+anti-CD8)(c), n = 7 per group (d). e Flow cytometry assessing IFNγ+, GzmB+ and Ki67+ CD8+ T cells in shNT or shUhrf1 tumors. n = 5 (shNT), 4 (shUhrf1). f, g Flow cytometry assessing CD69 expression (f) and cytokine production (g) in OT-I T cells co-cultured with sgNT or sgUhrf1 LG1233-OVA cells. n = 3 per group. h Gene set enrichment analysis (GO molecular function) of upregulated genes in sgUhrf1 tumors compared with sgNT tumors. n = 3 per group. i Flow cytometry determines the surface level of H2Kb-H2Db in LG1233 sgNT and sgUhrf1 cells. n = 4 per group. j Flow cytometry determines the surface level of HLA-ABC in sgNT and sgUHRF1 H2170 cells. n = 3 per group. k Flow cytometry measurement of cell surface OVA 257-264 (SIINFEKL) peptide bound to MHC-I complex in LG1233 sgNT and sgUhrf1 cells, with or without 5 ng/mL IFNγ for 16 h. n = 3 per group. Data are mean ± SEM (a–g, i–k). n indicates the number of biological (a–e, h) or technical (f, g and i–k) replicates. P values were determined using two-tailed Student’s t test (a, b, e–g, i–k), two-way ANOVA test (c, d) and one sided hypergeometric test then adjusted using multiple-test correction (h). MFI, mean fluorescence intensity; FDR, false discovery rate. Source data are provided as a Source Data file. All the data except h was repeated independently at least twice with similar results.